m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02848)
Name
NKS-01
Synonyms
14alpha-Hydroxy-4-androstene-3,6,17-trione
    Click to Show/Hide
Status
Discontinued in Phase 2
Structure
Formula
C19H24O4
InChI
1S/C19H24O4/c1-17-6-3-11(20)9-14(17)15(21)10-13-12(17)4-7-18(2)16(22)5-8-19(13,18)23/h9,12-13,23H,3-8,10H2,1-2H3/t12-,13+,17+,18+,19+/m0/s1
InChIKey
UKVVNEHFNYKGMX-KIVPVIKRSA-N
PubChem CID
6918079
TTD Drug ID
D0U9LL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aromatase (CYP19A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aromatase (CYP19A1) is a therapeutic target for NKS-01. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of NKS-01 through regulating the expression of Aromatase (CYP19A1). [1], [2]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Br J Clin Pharmacol. 2001 Dec;52(6):702-4. doi: 10.1046/j.0306-5251.2001.01488.x.